Archiv
Archiv anzeigen:
bis


Erythropoiesis-Stimulating Agents for Cancer-Associated Anemia

Brady L. Stein, MD, MHS reviewing Bohlius J et al. Blood Adv 2019 Apr 23

An update to 2010 guidelines


Unique Therapy for a Rare Blood Cancer

Michael E. Williams, MD, ScM reviewing Pemmaraju N et al. N Engl J Med 2019 Apr 25

Patients with untreated or relapsed blastic plasmacytoid dendritic-cell neoplasm achieved high response rates with tagraxofusp, a novel targeted cytotoxin.


Vitamin D Cancer Therapy?

David H. Ilson, MD, PhD reviewing Urashima M et al. JAMA 2019 Apr 9, Ng K et al. JAMA 2019 Apr 9, Barry EL et al. JAMA 2019 Apr 9

Vitamin D3 supplementation, compared with placebo, did not result in significant improvement in relapse-free or progression-free survival in two new trials.


Perioperative Chemotherapy for Resectable Gastric Cancer

David H. Ilson, MD, PhD reviewing Al-Batran S-E et al. Lancet 2019 Apr 10

The FLOT regimen is a new standard of care for patients who can tolerate triplet chemotherapy.


Prolonging Response in Acute Myeloid Leukemia

Michael E. Williams, MD, ScM reviewing Huls G et al. Blood 2019 Mar 28

Disease-free survival was longer with maintenance azacitidine than with observation in older patients who responded to induction chemotherapy.


DA-EPOCH-R vs. Standard R-CHOP for Diffuse Large B-Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Bartlett NL et al. J Clin Oncol 2019 Apr 2

Survival was not improved with DA-EPOCH-R in patients with newly diagnosed disease.


Pertuzumab plus Trastuzumab for HER2-Amplified Metastatic Colorectal Cancer

David H. Ilson, MD, PhD reviewing Meric-Bernstam F et al. Lancet Oncol 2019 Apr

Dual-targeted HER2 therapy had a modest signal of activity in patients with chemotherapy-refractory KRAS wild-type disease.


First-Line Pembrolizumab for Metastatic Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Mok TSK et al. Lancet 2019 Apr 4, Smit EF and de Langen AJ. Lancet 2019 Apr 4

Overall survival was improved with pembrolizumab versus chemotherapy, but only in patients with tumor proportion score ≥50%. However, the FDA has surprisingly expanded the indication for frontline pembrolizumab to include all patients with TPS ≥1%.


Detecting Extravascular Migratory Metastases in Pancreatic Cancer

Douglas G. Adler, MD, FACG, AGAF, FASGE reviewing Rustagi T et al. Clin Gastroenterol Hepatol 2019 Apr 3

Endoscopic ultrasound–guided sampling of perivascular soft-tissue cuffing identified metastases that were not found by CT or MRI in more than a quarter of patients.


Benralizumab for Hypereosinophilic Syndrome

Brady L. Stein, MD, MHS reviewing Kuang FL et al. N Engl J Med 2019 Apr 4

The monoclonal antibody against the interleukin-5 receptor was well tolerated and effective in reducing absolute eosinophil counts in symptomatic patients.


Archiv
Seite von 81
Editorial Member Board Empfehlungen

Prof. Dr. med. Christoph Rochlitz

Chefarzt Onkologie
Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.

Kommentar weiterlesen

Apalutamide for Castration-Resistant PSA-Only Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Smith MR et al. N Engl J Med 2018 Feb 8

Metastasis-free survival was significantly longer with apalutamide than with placebo.


Second-Line Olaparib for Gastric Cancer

David H. Ilson, MD, PhD reviewing Bang Y-J et al. Lancet Oncol 2017 Dec

Contrary to prior findings, adding olaparib to paclitaxel failed to improve survival in patients with disease progression following chemotherapy.


Predicting Response to Immunotherapy in Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Rizvi H et al. J Clin Oncol 2018 Jan 16

Assessment of tumor mutation burden using targeted next-generation sequencing may be predictive of benefit from PD-1 and PD-L1 inhibitors.


Prolonged Adjuvant Aromatase Inhibitor Treatment for Early Breast Cancer

William J. Gradishar, MD reviewing Blok EJ et al. J Natl Cancer Inst 2018 Jan 1, Goldvaser H et al. J Natl Cancer Inst 2018 Jan 1, Pohlmann PR and Isaacs C. J Natl Cancer Inst 2018 Jan 1

Outcomes were not superior with 5 versus 2.5 years of extended letrozole therapy.


Prognosis of Monoclonal Gammopathy of Undetermined Significance

David Green, MD, PhD reviewing Kyle RA et al. N Engl J Med 2018 Jan 18

Overall survival was significantly shorter among MGUS patients than among a matched control population in a long-term follow-up study.


Prognosis for BRCA-Mutated Breast Cancer

William J. Gradishar, MD reviewing Copson ER et al. Lancet Oncol 2018 Jan 11

Survival is similar between BRCA mutation carriers versus those with sporadic disease.


Electrical Field Therapy for Glioblastoma

Roy E. Strowd, MD reviewing Stupp R et al. JAMA 2017 Dec 19

Adding tumor-treating electrical-field therapy to maintenance temozolomide chemotherapy significantly improved survival in patients with newly diagnosed glioblastoma.


Atezolizumab for Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Powles T et al. Lancet 2017 Dec 18, Massari F and Di Nunno V. Lancet 2017 Dec 18

Overall survival was not improved with the PD-L1 inhibitor atezolizumab versus chemotherapy in patients with highest PD-L1 expression.


Pembrolizumab for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Balar AV et al. Lancet Oncol 2017 Sep 26

First-line therapy demonstrated antitumor activity in a phase II study.


Restarting Adjuvant Endocrine Therapy for Breast Cancer

William J. Gradishar, MD reviewing He W et al. J Natl Cancer Inst 2017 Oct 01

Disease-free survival is significantly improved in patients who restart therapy versus those who do not restart after discontinuation.